DIA Asia Meeting 2025

The Future of Health in APAC - Integrating Clinical Trials into Clinical Practice

17, July 2025
One Farrer Hotel, Singapore

Overview

The 2025 DIA Asia Meeting invites you to join an inspiring gathering of regulators, academia, clinicians, patient representatives, and industry leaders from across China, Korea, Japan, Singapore, Southeast Asia, and beyond. This year's theme, Integrating Clinical Trials into Clinical Practice, highlights the essential role of collaboration and innovation in driving better patient outcomes and transforming healthcare in Asia.

Together, we will explore cutting-edge topics, including:

1. Digital Health to Revolutionize Patient Care

Discover how AI and machine learning are shaping drug development, clinical trial execution, and operational efficiency in healthcare.

2. Unlocking the Power of Real-World Data (RWD)

Learn strategies to address operational and functional challenges, ensuring fit-for-purpose data assets from electronic medical records (EMR), claims, patient registries, genomics data, and more.

3. Advancing Precision Medicine

Discuss breakthroughs in targeted treatments for rare diseases and oncology, transforming care so patients receive the right treatment at the right time.

4. Enhancing Regulatory Oversight and Compliance

Examine the balance between regulatory and ethical oversight and the practical applications of regulatory science in clinical practice.

With deep dives into these pivotal topics, the conference will provide actionable insights into the latest trends in clinical research, AI, digital health and regulatory science, offering a platform to exchange best practices and drive healthcare transformation across the region.

Program Chair

Jing Ping, PhD, MBA
Precision for Medicine, Singapore.

Program Co-Chair

Yil-Seob Lee, MD, PhD
CHA Bundang Medical Center

Rie Matsui
Pfizer Japan R&D

Xiaojun (Wendy) Yan, MBA
DIA BOD, strategic advisor

Young Joo Park, MPH, PhD
Korea, Singapore and SEA, DIA

Program Committee

Joonwoo Bahn, MD, PhD
Asan Medical Center

Endang Hoyaranda
The Indonesian Association for The Study of Medicinals

Ken Lee, MD
Syneos Health

John Lim
Centre of Regulatory Excellence

Su Ling, PhD
Yeehong Business School, Shenyang Pharmaceutical University, China

Hiro Niimi
Japan, DIA

Jin Shun
Pharmagend Global Medical Services Pte Ltd

Tina Sun
TCRA

TongYan Wang
DIA China

Jack Wong
RNAscence Biotechnology

Kum Cheun Wong, PharmD
Novartis Asia Pacific Pharmaceuticals Pte.Ltd.

The Drug Information Association, Inc.
DIA Global Center: Washington, DC, USA | Basel, Switzerland | Beijing, China | Horsham, PA, USA | Mumbai, India | Tokyo, Japan

DIA volunteers, members, and staff provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications, and educational materials, throughout the year, all around the world.

DIAglobal.org

AGENDA | July 17, 2025 | Day 1 | ALL TIMINGS IN SGT

8.30 – 9.00 am	Registration
9.00 – 9.15 am	**Welcome / Congratulatory remark**
	Jing Ping Yeo, PhD, MBA, Vice President, Clinical Operations & Head, Asia Pacific Precision for Medicine, Singapore
9.15 – 10.00 am	Keynote address : The Future of Research in Healthcare
	Danny Soon, MBBS, CEO, Consortium for Clinical Research and Innovation (CRIS)
10.00 - 11:15 am	**Session 1** **Digital Health to Revolutionise Patient Care, improving Medical Outcomes and Enhance Operational Efficiency - AI and LLM Applications in Drug Development and Clinical Trial Execution**
	The integration of Artificial Intelligence (AI) and Large Language Model (LLM) into digital health is transforming patient care and clinical research on a global scale. US FDA have issued the guidances with Digital Health content including AI and EMA have also issued the reflection paper on the use of AI in the medicinal product lifecycle. This area is still evolving. This session will delve into the critical considerations for transforming patient care and clinical research, sharing experiences on developing and discussing AI use cases for clinical trials. Additionally, the future of the digital health ecosystem via AI and LLM will be discussed.
Session Chair	**Rie Matsui, RPh** Senior Director, Regional Labeling Head for APAC International Labeling, Pfizer Japan R&D **KumCheun Wong** Head Asia Pacific Regulatory Policy Novartis
10.00 – 10.25 am	Ethics in Digital Health in Relation to Patient Care and Clinical Research
	Siang Hui Lai, MBBS, DMJ(Path), FRCPath, Chair, CIRB, SingHealth
10.25 - 10.50 am	The measure of you - AI enhanced digital endpoint to accelerate clinical research
	Echo Chen, PhD, Founder and CEO of Luca Healthcare
10.50 - 11.15 am	How AI Enables Patient-Initiated Journeys Toward Treatment
	Shoko Suzuki, Global PdM, Ubie Inc.
11.15 - 11:30 am	**Break**
11.30 - 12.45 am	**Session 2** **Unlock the Power of RWD to Drive innovation in Healthcare**
	Real-world data is a cornerstone of modern healthcare innovation. This session addresses the complexities and benefits of leveraging data from electronic medical records (EMR), claims, patient registries, cross sectional studies and genomics to drive evidence generation and improve patient care. The regional collaboration activities for RWD studies will be covered.
Session Chair	**Yil-Seob Lee, MD, PhD** Professor Dept. of Clinical Pharmacology & Therapeutics, CHA University **Joonwoo Bahn, MD, PhD** Professor Asan Medical Center
11.30 - 11.55 am	RWE as a first option
	Jeff Lange, PhD, Senior Director of Observational Research - Asia, Amgen
11.55 am - 12.20 pm	Accessibility and Applicability of Real-World Data in Asia: The DIANA Study (DIA Asia Network for Advancing Regulatory Innovation)
	Judy Shin, PhD, Chair Professor, Department of Biohealth Regulatory Science at School of Pharmacy, SungKyunKwan University Korea
12.20 12.45 pm	How RWE guides the decision making in regulatory: drawing from FDA, EMA and PMDA
	Kiyoshiro Tanaka, MMSc, Biostatistical reviewer, PMDA
12.45 - 1.30 pm	**Lunch**

AGENDA | July 17, 2025 | Day 1 | ALL TIMINGS IN SGT

1.30 - 2.45 pm	**Session 3** **Improving the Precision of Personalized Medicine in Targeted Treatments (Rare disease, Oncology)**
	According to FDA, precision medicine—sometimes known as personalized medicine - tailors disease prevention and treatment for individual variability (e.g., genetic and lifestyle differences among patients). The goal of precision medicine is to match the right treatment at the right dosage for each individual patient at the right time. Over the years, personized medicine is one of important areas for drug and medical devise development. We have seen some progresses, but challenges still remain. This session will present the progress of precision medicine with a focus on drug development and discuss the opportunities and challenges. Three leading experts will discuss cutting-edge advancements in biomarker discovery, clinical development/medical practice, and regulatory considerations that are key drivers in this area. Together, these speakers will provide a comprehensive overview and share their insight on how to improve the precision of personalized medicine in the development of target therapies.
Session Chair	**Wendy Yan, MBA** DIA BOD, Strategic advisor **Su Ling, PhD** Research Fellow, Yeehong Business School, Shenyang Pharmaceutical University, China
1.30 - 1.45 pm	The National Precision Medicine Programme: Enabling Drug Discovery & Development
	Seow Shih Wee, PhD, Senior Director, Precision Health Research, Singapore(PRECISE)
1.45 - 2.00 am	Finding the right drug for the patient: quest in clinical research and support by regulatory framework
	Xiaoyuan Chen, PhD, Office Director, Clinical Research Institute Tsinghua Medicine, Tsinghua University
2.00 - 2.15 pm	Improving the precision of personalized medicine in targeted treatment: Industry perspective
	Cristina Chang, MD, PhD, Chief Medical Officer & VP Clinical Science and Medical Affairs, Harvest Integrated Research Organization, China
2.15 - 2.30 pm	Precision medicines: An update on clinical biomarker and CDx regulation in the EU
	Hilke Zander, PhD, MDRA, Clinical Assessor, Section Monoclonal Antibodies, Paul-Ehrlich-Institute Langen, Germany
2.30 - 2.45 pm	Q&A
2.45 - 4.00 pm	**Session 4** **Increase Regulatory Oversight and Compliance under Regulatory Science.**
	This session will explore the critical role of regulatory oversight and compliance in integrating clinical trials into clinical practice. **Featuring speakers from key health authorities across Asia**, the session will address how regulatory frameworks can adapt to emerging technologies and regulatory science, while ensuring ethical oversight, transparency, and global harmonization of standards. Attendees will gain insights into balancing innovation with rigorous regulatory standards, with perspectives from regulators on navigating compliance challenges and fostering patient-centric approaches in a rapidly evolving clinical research landscape.
Session Chair	**Jin Shun** BD & RA Head Pharmagend Global Medical Services Pte Ltd **Jing Ping Yeo PhD, MBA** Vice President, Clinical Operations & Head, Asia Pacific Precision for Medicine, Singapore
2.45 - 3.10 pm	Recent Progress in Clinical trials: Insights from Shanghai Regulatory Science research and Exploration of the Innovative Drug Clinical Trial Pilot Program
	Sun Bo, PhD, Deputy Head of Pharmacology and Clinical Trials Department, Shanghai Center for Drug Evaluation and Inspection (SCDEI), China
3.10 - 3.35 pm	Overview of Annex 2 of ICH E6 (R3) Good Clinical Practice (GCP) guideline
	Sumitra Sachidanandan, Regulatory Consultant Innovation Office & Clinical Trials Branch, Health Sciences Authority, Singapore
3.35 - 4.00 pm	Advancing Japan Regulatory Science in Collaboration with Stakeholders
	Manami Nomura, Principal Reviewer, Office of Regulatory Science Coordination, PMDA
4.00 ~ 4.15 pm	**Tea break**

AGENDA | July 17, 2025 | Day 1 | ALL TIMINGS IN SGT

4.15 - 5.00 pm	**Session 5** **Modernising Clinical Trials: Trends and Opportunities**
	After the global COVID-19 pandemic, the entire pharmaceutical and healthcare ecosystem had to rapidly modernize technology and processes to advance medicine and deliver life-saving therapies to patients. Traditional trial methods, such as centralized trial sites, in-person monitoring, limited use of real-world data, etc., gave rise to innovative solutions that represented significant steps towards improving patient centricity and reducing the burden of clinical trial conduct. The industry quickly recognized these solutions, such as decentralized trial structures, digital health technologies, real-world data, and more patient-centric approaches, as opportunities to be normalized in future clinical trials. This panel discussion will assess the progress and current state of modernization in clinical trials since 2020. The sustainability of change, known challenges, and new opportunities for further modernization will be discussed among a multi-stakeholder group.
4.15 - 4.45 pm	Modernising Clinical Trials: Trends and Opportunities
	Patrice Wright, Director of Health Authority Engagement, TransCelerate Biopharma
4.45 - 5.00 pm	**Panel Discussion**
	Panelists: **Patrice Wright**, TransCelerate Biopharma **Tina Sun**, Novartis **Shigeru Nakaji**, Head of RD Operations, RD Strategy and Operations, CRDO Office, Astellas Pharma
5.00 - 5.10 pm	Closing remarks
	Young Joo Park, MPH, PhD, Vice President, Korea, Singapore, and SEA, DIA

REGISTRATION FORM : Register online or forward to DIA
tel +82-10-9014-9582

Aisa Meeting 2025

Event #85225 • 17 July 2025 | One Farrer Hotel, Singapore

REGISTRATION

Register online at the link below or complete this registration form and email to our Korea Office

Online Registration For Payment via Credit Card, please access here

DIA will send participants a confirmation letter within 10 business days after receipt of their registration.

Registration Fees If DIA cannot verify your membership, you will be charged the nonmember fee. Registration fee includes refreshment breaks and reception (if applicable), and will be accepted by mail, fax, or online.

25% Discount is applicable for those who attend both events!
*Please note that the discount is only available when registering for both events at the same time. **Before WEB registration, please contact** Korea@diaglobal.org"

			REGISTRATION FEE (SGD)	
	Early Bird (until June 30, 2025)		15-16 JULY 2025 DIA SINGAPORE ANNUAL MEETING 2025	17 JULY 2025 DIA ASIA MEETING 2025
MEMBER	**Academic**	**Early Bird**	❑ **320**	❑ **200**
		After July 01, 2025	❑ **420**	❑ **260**
	Government	**Early Bird**	❑ **270**	❑ **170**
		After July 01, 2025	❑ **370**	❑ **230**
	Industry	**Early Bird**	❑ **700**	❑ **420**
		After July 01, 2025	❑ **900**	❑ **540**
NON-MEMBER	**Academia**	**Early Bird**	❑ **420**	❑ **260**
		After July 01, 2025	❑ **530**	❑ **330**
	Government	**Early Bird**	❑ **370**	❑ **230**
		After July 01, 2025	❑ **480**	❑ **300**
	Industry	**Early Bird**	❑ **900**	❑ **540**
		After July 01, 2025	❑ **1,000**	❑ **600**
Patient / Patient Advocacy Groups			❑ **200**	❑ **120**

Please check the applicable category:
❑ Academia ❑ Government ❑ Industry

Last Name

First Name

Degrees ❑ Dr. ❑ Mr. ❑ Ms.

Job Title

Company

Address (As required for postal delivery to your location)

City State Zip/Postal Country

email **Required for confirmation**

Phone Number **Required**

Join DIA now to save on future meetings and to enjoy the benefits of membership for a full year: www.DIAglobal.org/Membership

❑ I **DO** want to be a DIA member
❑ I **DO NOT** want to be a DIA member

CONTACT INFORMATION

tel: +82-10-5426-8827
email: Korea@DIAglobal.org
www.diaglobal.org

DIA Terms and Conditions

CANCELLATION POLICY: On or before 12 Aug, 2024
Administrative fee that will be withheld from refund amount: the administrative fee that will be withheld from refund amount is 25 % of the delegate fee
Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid.
Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but **membership is not transferable**. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

EVENT STREAM AND RECORDING
If you attend a DIA event, we make video and audio recordings of events (both face to face and online) that may include your participation in the event, including your image, questions and comments. To view our full photography and video recording policy, click **here**. (https://www.diaglobal.org/general/photography-policy)

PRIVACY STATEMENT
The personal information you request will be used for the purpose of sending conference information from DIA. In addition, in the web conference, we will use the information with the name of the company or organization and the name of everyone who participates, and it will be used for networking with participants, related parties, exhibiting companies for the period and about two weeks after the event. .. By submitting this application form, it is interpreted that you have consented to the above handling of personal information, but if you do not agree, please contact DIA.

By signing below I confirm that I agree with DIA's Terms and Conditions of booking. These are available from the office or online by clicking **here**. (https://www.diaglobal.org/general/photography-policy)

Signature Date

DIA MEMBERSHIP

Join DIA now to save on future meetings and to enjoy the benefits of membership for a full year: www.DIAglobal.org/Membership

❑ I **DO** want to be a DIA member
❑ I **DO NOT** want to be a DIA member

The annual membership fee is 250 SGD. To view the benefits of the membership, please click the link.

PAYMENT OPTIONS

Register online at **www.DIAglobal.org** or check payment method.

❑ **BANK TRANSFER:**
You will recieve an invoice with bank information detail by email after registration completion.
All local and overseas charges incurred for the bank transfer must be borne by payer.

❑ **CREDIT CARD (VISA OR MASTERCARD OR AMEX ONLY)**

❑ **VISA** ❑ **MC** ❑ **AMEX** Exp. (mm/yy) _____

Card No.

Cardholder Name

Signature

DIA